Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11454847 | 0.88 | ALDH1A1 (0.34) | L3MBTL3L3MBTL1 | |
| SCHEMBL3355983 | 0.86 | OPRL1 (0.33) | — | |
| SCHEMBL27811174 | 0.86 | ALDH1A1 (0.33) | — | |
| SCHEMBL7369318 | 0.86 | CYP2D6 (0.31) | — | |
| SCHEMBL7008001 | 0.83 | — | — | |
| SCHEMBL9687115 | 0.79 | HPGD (0.33) | — | |
| SCHEMBL10412770 | 0.79 | — | — | |
| SCHEMBL2235706 | 0.79 | L3MBTL1 (0.44) | L3MBTL3L3MBTL1 | |
| SCHEMBL15967645 | 0.73 | — | — | |
| SCHEMBL6543647 | 0.72 | L3MBTL1 (0.42) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358899-B2 | Thyroid hormone receptor agonists and uses thereof | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| EP-4574208-A2 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-06-25 | — | — | EP | disclosed |
| EP-3807267-B1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-03-19 | — | — | EP | disclosed |
| EP-4493556-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119301116-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240360106-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2024-10-31 | — | — | US | disclosed |
| US-11964964-B2 | Thyroid hormone receptor agonists and uses thereof | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-04-23 | — | — | US | disclosed |
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| EP-2223086-B2 | FLUORESCENT COMPOUNDS - LABELING DYES | BIOTIUM INC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160033520-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9097667-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| CN-101946171-B | Fluorescent compounds | BIOTIUM INC | 2014-03-12 | — | — | CN | disclosed |
| EP-2223086-B1 | FLUORESCENT COMPOUNDS - LABELING DYES | BIOTIUM INC (US) | 2013-03-20 | — | — | EP | disclosed |
| CN-102361887-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2012-02-22 | — | — | CN | disclosed |
| CN-101946171-A | Fluorescent compounds | BIOTIUM INC | 2011-01-12 | — | — | CN | disclosed |
| EP-2223086-A1 | FLUORESCENT COMPOUNDS | Biotium Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009078970-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964964-B2 | Thyroid hormone receptor agonists and uses thereof | TSHR, THRA, TRHR | L3MBTL3 4145/4885L3MBTL1 3828/4885 |
| US-20240360106-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | TSHR, THRA, TRHR | L3MBTL3 4145/4885L3MBTL1 3828/4885 |
| US-12358899-B2 | Thyroid hormone receptor agonists and uses thereof | TSHR, THRA, TRHR | L3MBTL3 4145/4885L3MBTL1 3828/4885 |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | MKI67, CD68, CA5B | L3MBTL3 1302/4885L3MBTL1 1499/4885 |
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | L3MBTL3 3118/4885L3MBTL1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.